

CLINICAL TRIAL

NCT03319849



Interventional



Phase 3

Retinal RED

A Study to Determine the Safety and Efficacy of Renexus[®] in Macular Telangiectasia Type 2

Rare Eye Disease concerned by the trial :
Macular Telangiectasia Type 2

Status of the trial : recruiting
Orphan drug recognition : N/A

Inclusion criteria : [Click here to see detailed criteria](#)

Exclusion criteria : [Click here to see detailed criteria](#)



Inclusion
opening date : 06/02/2018



Inclusion closing
date (previsionnal) : 31/03/2022

Children



Adults



Within ERN-EYE members



Principal location of the trial :
Eye Centre, University Hospital Freiburg
Hugstetter Str. 55, 79106
Freiburg im Breisgau, Germany

[Contact details](#)




Principal investigator name :
Thomas Reinhard



Other investigators :
Daniel Böhringer
Felicitas Bucher

Funder type : Industry



[More informations](#)